Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat DDI with Statins and Sulfasalazine
NCT03801733Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jun 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (5 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under plasma concentration-time curve from time 0 to last quantifiable concentration up to 10 weeks, Area under plasma concentration-time curve from time 0 to infinity up to 10 weeks and 2 more. Started Jun 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03801733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801733.